Clinical trial
An Open Label, Observational Clinical Study to Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Have Any Grade of Adverse Events and Early Molecular Response Within 3 Months of Frontline Dasatinib Therapy
NCT04150471 is registered in ClinicalTrials.gov with Seoul St. Mary's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Observational Clinical Study to Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Have Any Grade of Adverse Events and Early Molecular Response Within 3 Months of Frontline Dasatinib Therapy
- Lead sponsor
- Seoul St. Mary's Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- October 18, 2018
- Completion date
- December 30, 2023
- Enrollment
- 79 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic myelocytic leukemia